Global Idiopathic Short Stature Treatment Market - 2023-2030

Global Idiopathic Short Stature Treatment Market - 2023-2030

Global Idiopathic Short Stature Treatment Devices Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.

Idiopathic short stature (ISS) is defined as a condition characterized by a height more than 2 standard deviations below the corresponding average height for a given age, sex, and population, without findings of disease.

GH administered to children with ISS induces an adult height gain of between 3 and 7 cm, depending on the duration of treatment. There are fewer adverse events associated with GH therapy in children with ISS when compared to side-effect profiles observed in other GH-treated disorders.

Market Dynamics: Drivers & Restraints

Increasing incidence of the idiopathic short stature

The increase in the number of cases of the condition is expected to drive the market growth. Aromatase inhibitors (AIs) are the compounds that block the conversion of androgens to estrogens and reduce the action of estrogens at the growth plate. For this reason, AIs have been used to intervene in height outcomes in boys with GH deficiency, idiopathic short stature, and constitutional growth delay.

According to the report published by Frontiers, it is estimated that a large number of people are undergoing a diagnosis of short stature and out of it 80% of people are estimated to suffer from idiopathic short stature condition. Thus, an increase in the patient count is expected to drive the market growth.

Restraint

Limited awareness about the treatment

Limited awareness about the available treatment options is expected to hinder the market. This is because people suffering from the condition are unaware of their disease which would directly impact the market growth. Additionally, the availability of only a few treatment options and the cost of the treatment could affect the market growth.

Segment Analysis

The global idiopathic short stature treatment market is segmented based on treatment type, end-user, and region.

Growth hormone therapy segment accounted for 56.3% of the market share

The growth hormone therapy segment holds the dominant position in the market share because Growth hormone therapy is the FDA-approved treatment procedure that is considered to be safe when compared to the other procedures. The safety and efficiency of the treatment are expected to hold the segment in the dominant position.

The child who undergoes growth hormone treatment for three to four years for idiopathic short stature will see their final height improved by two to four inches. Growth hormone injection treatment is prescribed for children who have been diagnosed with growth hormone (GH) deficiency and other conditions causing short stature.

Several other tests must be conducted first to confirm GH deficiency for which GH therapy is indicated. These tests may include stimulation tests, MRIs, and X-rays. GH treatment is a safe, effective way to treat growth hormone deficiency associated with short stature.

The growth hormone produced in the laboratory will be identical to the hormone produced by the body which reduces the side effects of the treatment. GH is given through a subcutaneous injection which enters into the fatty tissue just beneath the surface of the skin. Thus, the above factors are estimated to increase the demand for growth hormone therapy and increase the segment growth in the forecast period.

Geographical Analysis

North America is expected to hold a significant position in the global idiopathic short stature treatment market share

North America is expected to hold the dominant position in the market share due to the presence of the large major players in the region and also the increased technological advancements in developing new treatment procedures and the presence of a large patient population.

For instance, in June 2023, Pfizer Inc. and OPKO Health Inc. received the U.S. Food and Drug Administration (FDA) approval for NGENLA which is a once-weekly, human growth hormone analog indicated for the treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone.

The increase in clinical trials and the increase in the new treatment options in the region are expected to drive market growth and is expected to hold the region in the dominant position.

COVID-19 Impact Analysis

COVID-19 has shown a significant impact on the idiopathic short stature market growth. During this period, pharmaceutical companies have shifted their focus towards the manufacturing of COVID-19 medicine. The lockdown impacted the supply chain of raw materials for the manufacturing of the drugs. Hospitals have been closed and patient visit has also been reduced. Thus, it has impacted the growth of the market.

Market Segmentation

By Treatment Type
• Drug Type
BBT-031
Somatropin
Somatropin S
Others
• Therapy
Growth Hormone Therapy
Aromatase Inhibitors and Low-dose Androgen Therapy

By End-User
• Hospitals
• Research Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The leading companies with a significant market share include Pfizer Inc., GNH India, Ferring Pharmaceuticals Inc., Novo Nordisk, Genentech, Inc., Bolder Bio Technology, Inc. and Eli Lilly and Company among others

Why Purchase the Report?
• To visualize the global idiopathic short stature treatment market segmentation based on treatment type, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of idiopathic short stature treatment with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global idiopathic short stature treatment market report would provide approximately 52 tables, 56 figures, and 174 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies